Group 1: Financial Performance - The company's revenue and net profit declined in 2025 due to macroeconomic conditions, industry cycles, and market competition, with the raw material pharmaceutical intermediate business being the primary factor affecting revenue [3] - The company expects to release its Q1 report on April 21, 2026 [3] - Contract liabilities significantly decreased, indicating revenue conversion rather than a loss of orders, which does not directly impact future performance [2] Group 2: Business Strategy and Growth - The CDMO (Contract Development and Manufacturing Organization) business is anticipated to be the main driver of performance growth in the next 1-2 years [4] - The company is focusing on expanding its CDMO business in veterinary medicine, benefiting from the global demand for animal health care [4] - The company plans to continue increasing R&D investment, maintaining it at around 6% of revenue, to support sustainable business development [3] Group 3: Product Development and Market Expansion - The company has completed clinical enrollment for the drug Semaglutide for weight loss and diabetes, adhering to regulatory processes to expedite product launch [2] - The company is developing new products in the medical beauty sector, leveraging its chemical synthesis and synthetic biology platforms [4] - The new peptide workshop is under construction and will meet commercial production needs for peptide projects once operational [5] Group 4: Market Position and Competition - The company aims to maintain and enhance its market share through effective market expansion and customer relationship management, focusing on cost and quality competitiveness [4] - The CDMO business's gross margin rose to over 48% in Q4 2025, with efforts to maintain or improve this margin through technology upgrades and cost control [5] - The company is expanding its overseas market presence, with expected increases in sales volume, although profitability will be influenced by market competition [5]

Core Insights - The company reported a revenue growth of 14.93% to 242 million yuan in the first half of 2025, with net profit attributable to shareholders increasing by 4.74% to 60.79 million yuan [1] Revenue and Profit Performance - Revenue increased by 14.93% to 242 million yuan [1] - Net profit attributable to shareholders rose by 4.74% to 60.79 million yuan [1] Product Development and Market Share - The company has focused on developing potential products, including raw materials and intermediates such as sucralfate, phenacetin, atorvastatin calcium, and PHBA, achieving high market shares [1] - Products like escitalopram oxalate, parecoxib sodium, and GABOB are expanding in sales and market share [1] Business Segment Performance - Sales of raw materials and intermediates grew by 13.94% and 29.24% year-on-year, respectively, driving overall performance [1] Market Expansion and Global Strategy - The company has optimized its market structure through global expansion, with domestic market stability and significant growth in international sales, which increased by 53.04% year-on-year [1] - The company continues to enhance its supplier qualification process and strengthen market development in the Americas and Europe, leading to a steady increase in market share [1]

Group 1: Development Direction and Progress - The company focuses on high-end complex formulations, particularly in markets with large scale, high technical difficulty, and few competitors, to establish a unique competitive advantage [2][3] - Currently, the company has three peptide injection products (including APIs) approved for market in the U.S., with four more under FDA review [2] - The company aims to accelerate the registration process in Europe and expand into other global markets, leveraging approvals obtained in the U.S. [2] Group 2: Internationalization Efforts - The company has consistently pursued an internationalization strategy, successfully passing GMP inspections from the U.S. FDA, EU EMA, Philippines FDA, and Saudi Arabia SFDA [3] - Products such as thymosin alpha-1 and other injections have received FDA approval and have been exported to the U.S. [3] - The company plans to continue submitting DMF and ANDA applications in the U.S. and EU to further its internationalization efforts [3] Group 3: Raw Material Development - The company's thymosin alpha-1 has passed technical review by the Italian Medicines Agency (AIFA), and its somatostatin API has obtained a CEP certificate [3] - Other raw material businesses are being developed as a key focus for future growth [3] Group 4: Quality Management and CMO Cooperation - The subsidiary Ningbo Shuangcheng has passed the U.S. FDA CGMP inspection, ensuring compliance with quality management standards [3] - The company is actively pursuing CMO collaborations, particularly with major clients, while ensuring the production of its proprietary products [3]